Small cell lung cancer (SCLC; accounting for approximately 13%–15% of all lung cancers)
is an exceptionally lethal malignancy characterized by rapid doubling time and high …

The treatment landscape for metastatic renal cell carcinoma (mRCC) and urothelial
carcinoma (mUC) has evolved rapidly in recent years with the approval of several …

Background Platinum-based chemotherapy is standard-of-care first-line treatment for
advanced urothelial carcinoma. However, progression-free survival and overall survival are …

Bladder cancer is a common malignancy that has a relatively poor outcome. Lack of culture
models for the bladder epithelium (urothelium) hampers the development of new …

Studies of the relationship between the gastrointestinal microbiota and outcomes in
allogeneic hematopoietic stem cell transplantation (allo-HCT) have thus far largely focused …

Immune checkpoint therapy (ICT) can produce durable antitumor responses in metastatic
urothelial carcinoma (mUCC); however, the responses are not universal. Despite multiple …

Background Immune checkpoint inhibitors (ICIs) represent an appealing treatment for
patients with advanced urothelial cancer (aUC) and a poor performance status (PS) …

With the mechanistic understanding of immune checkpoints and success in checkpoint
blockade using antibodies for the treatment of certain cancers, immunotherapy has become …

Bladder cancer (BC) is a complex and highly heterogeneous stem cell disease associated
with high morbidity and mortality rates if it is not treated properly. Early diagnosis with …

Background While immune checkpoint inhibitors (ICIs) are approved in the first-line (1L)
setting for cisplatin-unfit patients with programmed death-ligand 1 (PD-L1)-high tumors or for …